Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

SELL
$40.25 - $52.99 $13,081 - $17,221
-325 Reduced 25.53%
948 $39,000
Q1 2024

May 14, 2024

BUY
$47.98 - $54.4 $61,078 - $69,251
1,273 New
1,273 $69,000
Q3 2023

Nov 15, 2023

SELL
$57.89 - $64.73 $115 - $129
-2 Reduced 0.15%
1,299 $75,000
Q2 2023

Aug 14, 2023

BUY
$63.71 - $70.74 $700 - $778
11 Added 0.85%
1,301 $83,000
Q1 2023

May 22, 2023

BUY
$65.71 - $74.53 $78,917 - $89,510
1,201 Added 1349.44%
1,290 $89,000
Q1 2023

May 15, 2023

SELL
$65.71 - $74.53 $74,449 - $84,442
-1,133 Reduced 92.72%
89 $129,000
Q4 2022

Feb 15, 2023

BUY
$68.48 - $81.09 $12,463 - $14,758
182 Added 17.5%
1,222 $88,000
Q3 2022

Nov 15, 2022

BUY
$0.13 - $76.84 $13 - $7,684
100 Added 10.64%
1,040 $74,000
Q2 2022

Aug 15, 2022

SELL
$72.62 - $79.98 $217 - $239
-3 Reduced 0.32%
940 $73,000
Q1 2022

May 11, 2022

SELL
$61.48 - $73.72 $1,106 - $1,326
-18 Reduced 1.87%
943 $68,000
Q4 2021

Mar 09, 2022

BUY
$53.63 - $62.52 $2,681 - $3,126
50 Added 5.49%
961 $60,000
Q2 2021

Aug 23, 2021

BUY
$61.91 - $67.42 $11,639 - $12,674
188 Added 26.0%
911 $62,000
Q3 2020

Nov 30, 2020

SELL
$57.43 - $63.64 $2,354 - $2,609
-41 Reduced 5.37%
723 $46,000
Q1 2020

May 08, 2020

BUY
$46.4 - $67.43 $1,902 - $2,764
41 Added 5.67%
764 $47,000
Q4 2018

Feb 13, 2019

SELL
$48.76 - $63.23 $923,026 - $1.2 Million
-18,930 Reduced 96.32%
723 $38,000
Q3 2018

Nov 13, 2018

BUY
$55.19 - $62.25 $42,220 - $47,621
765 Added 4.05%
19,653 $960,000
Q2 2018

Jul 31, 2018

SELL
$50.53 - $62.98 $13,137 - $16,374
-260 Reduced 1.36%
18,888 $1.12 Million
Q1 2018

May 21, 2018

BUY
$59.92 - $68.98 $211,817 - $243,844
3,535 Added 22.64%
19,148 $1.21 Million
Q4 2017

Feb 01, 2018

BUY
$59.94 - $65.35 $935,843 - $1.02 Million
15,613
15,613 $957,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Front Row Advisors LLC Portfolio

Follow Front Row Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Front Row Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Front Row Advisors LLC with notifications on news.